Compare FNWD & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWD | TNYA |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.2M | 178.5M |
| IPO Year | 1996 | 2021 |
| Metric | FNWD | TNYA |
|---|---|---|
| Price | $36.18 | $0.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $37.50 | $5.33 |
| AVG Volume (30 Days) | 4.6K | ★ 5.0M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | ★ 54.96 |
| EPS | ★ 1.88 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.40 | N/A |
| Revenue Next Year | $5.44 | $1,456.12 |
| P/E Ratio | $19.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.46 | $0.36 |
| 52 Week High | $39.99 | $2.35 |
| Indicator | FNWD | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 45.32 | 43.92 |
| Support Level | $35.25 | $0.66 |
| Resistance Level | $38.79 | $0.70 |
| Average True Range (ATR) | 0.74 | 0.06 |
| MACD | -0.16 | -0.02 |
| Stochastic Oscillator | 26.81 | 21.90 |
Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.